Galapagos NV (GLPG.AS)
| Previous close | 27.34 |
| Open | 27.16 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 26.74 - 27.50 |
| 52-week range | 26.38 - 41.92 |
| Volume | |
| Avg. volume | 84,536 |
| Market cap | 1.778B |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings date | 03 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.00 |
Globe NewswireGalapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 202
- Globe Newswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent Non-Executive Director The appointments of D
ZacksDown -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG)
The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
